
Name
PEBA
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for PEBA
Name
Alternate Names
Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar
Abbreviations
EPEG
VP-16
VP-16-213
Category
Chemotherapy
Subcategory
Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid
NSC Number
141540
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin
Abbreviations
ADM
ADR
ADRI
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
123127
Primary Site
Histology
None
Remarks
Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
Name
Alternate Names
Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo
Abbreviations
BLE
BLEO
BLM
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
125066
Primary Site
Histology
None
Remarks
FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.
Coding
This drug should be coded
